Across TCGA pan-cancer cohorts, BOD1L2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BOD1L2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher BOD1L2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BOD1L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SARC, SKCM, and UCEC are the cancer types where BOD1L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.095	0.632	.002	6	view →
SKCM	DFS	Median	All	0.061	0.208	.007	6	view →
UCEC	DFS	Median	All	1.000	0.636	.042	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: BOD1L2 tumor-vs-normal RNA expression · all BOD1L2 data types